The structure of the mouse glutamic acid decarboxylase-like protein 1 (GADL1) is described. The structure provides new insights into the function of GADL1 and related decarboxylases.
Keywords: decarboxylases, pyridoxal phosphate, catalysis, conformational change
Abstract
Pyridoxal 5′-phosphate (PLP) is a ubiquitous cofactor in various enzyme classes, including PLP-dependent decarboxylases. A recently discovered member of this class is glutamic acid decarboxylase-like protein 1 (GADL1), which lacks the activity to decarboxylate glutamate to γ-aminobutyrate, despite its homology to glutamic acid decarboxylase. Among the acidic amino acid decarboxylases, GADL1 is most similar to cysteine sulfinic acid decarboxylase (CSAD), but the physiological function of GADL1 is unclear, although its expression pattern and activity suggest a role in neurotransmitter and neuroprotectant metabolism. The crystal structure of mouse GADL1 is described, together with a solution model based on small-angle X-ray scattering data. While the overall fold and the conformation of the bound PLP are similar to those in other PLP-dependent decarboxylases, GADL1 adopts a more loose conformation in solution, which might have functional relevance in ligand binding and catalysis. The structural data raise new questions about the compactness, flexibility and conformational dynamics of PLP-dependent decarboxylases, including GADL1.
1. Introduction
Pyridoxal 5′-phosphate (PLP), or vitamin B6, is a versatile cofactor that is involved in many enzymatic reactions spanning multiple enzyme classes and chemical reactions (Percudani & Peracchi, 2003 ▸). PLP-dependent decarboxylases constitute a large family of enzymes that catalyze a range of metabolic reactions. Many of these enzymes catalyze biologically well defined processes; inactivating mutations affecting them are associated with severe phenotypes, and some of them are treatment targets in human disease (Baekkeskov et al., 1990 ▸; Eliot & Kirsch, 2004 ▸; El-Sayed & Shindia, 2011 ▸; Paiardini et al., 2014 ▸; Sköldberg et al., 2004 ▸).
Despite extensive research, the biological functions of many PLP-dependent enzymes are still unclear. One such enzyme is glutamic acid decarboxylase-like protein 1 (GADL1), which was originally named based on its sequence homology to glutamic acid decarboxylase (GAD), which synthesizes the inhibitory neurotransmitter γ-aminobutyric acid (GABA; Fenalti et al., 2007 ▸). However, GADL1 has no reactivity towards glutamic acid and therefore is unlikely to be involved in GABA signalling (Liu et al., 2012 ▸; Winge et al., 2015 ▸). It has been suggested that GADL1 is involved in taurine production (Liu et al., 2012 ▸). On the other hand, in our recent comparative study of GADL1 and cysteine sulfinic acid decarboxylase (CSAD), an enzyme homologous to GADL1 that is involved in taurine biosynthesis, we showed that these enzymes act differently. Compared with CSAD, the activity of GADL1 towards cysteine sulfinic acid (CSA) as a substrate is much lower, and GADL1 has a stronger preference for aspartate, suggesting that GADL1 may be involved in the biosynthesis of β-alanine and its peptide derivatives, such as the neuroprotectant carnosine (Min et al., 2008 ▸; Park et al., 2014 ▸; Winge et al., 2015 ▸).
We showed in our earlier study that mouse and human brain have distinct patterns of expression of CSAD and GADL1 (Winge et al., 2015 ▸). Whereas both CSAD and GADL1 were expressed in neurons, only the CSAD mRNA was detected in astrocytes. Using a homology model of GADL1 based on the crystal structure of human CSAD (HsCSAD), we performed in silico screening of potential substrate analogues and discovered the first generation of inhibitors with partial selectivity against either GADL1 or CSAD. However, detailed mechanistic studies have been hampered by the lack of structural information.
In this study, we describe the crystal structure of mouse GADL1 (MmGADL1). Additionally, we used small-angle X-ray scattering (SAXS) to elucidate the solution shape of MmGADL1. The overall fold of MmGADL1 is similar to those of CSAD and other close homologues, with a flexible loop, not defined in electron density, from the apposing monomer covering the active site, which is possibly relevant in catalysis. SAXS data demonstrate that MmGADL1 adopts a loosened state in solution, which might correspond to an open conformation significant for cofactor or substrate binding.
2. Materials and methods
2.1. Macromolecule production
2.1.1. Construct preparation, protein expression and purification
The expression vector for MmGADL1 was prepared in the Gateway system using pTH27 (Hammarström et al., 2006 ▸) as the destination vector. Cloning involved a two-step PCR protocol and homologous recombination into Gateway vectors using standard procedures. The resulting construct codes for an N-terminal His6 tag, a Tobacco etch virus (TEV) protease cleavage site and MmGADL1 residues 1–502 (UniProt entry E9QP13). A longer isoform of MmGADL1 also exists (UniProtKB entry Q80WP8), and the construct corresponds to residues 49–550 of this isoform.
2.1.2. Expression and purification of MmGADL1
His6-tagged MmGADL1 was expressed in Escherichia coli BL21-CodonPlus(DE3)-RIPL cells (Stratagene) at 288 K using 150 mM IPTG induction. Cell pellets were lysed by sonication in a buffer consisting of 50 mM sodium phosphate buffer pH 7.4, 500 mM NaCl, 20 mM imidazole, 0.2 mg ml−1 lysozyme, 1 mM MgCl2, 2 mM pyridoxine hydrochloride and cOmplete EDTA-free protease inhibitors (Roche). Phenylmethylsulfonyl fluoride was added to 1 mM immediately following sonication. The unclarified lysate was applied directly onto an IMAC HiTrap TALON crude column (GE Healthcare). The column was washed with 50 mM sodium phosphate pH 7.4, 500 mM NaCl, 50 mM sodium phosphate pH 7.4, 500 mM NaCl, 20 mM imidazole. Elution was carried out with 100 mM imidazole in 50 mM sodium phosphate pH 7.4, 500 mM NaCl. Size-exclusion chromatography was performed using a Superdex HR 200 column (GE Healthcare) equilibrated with 20 mM HEPES, 200 mM NaCl pH 7.5.
2.2. Crystallization
Initial crystallization conditions for MmGADL1 were obtained from the JCSG-plus screen (Molecular Dimensions) using sitting-drop vapour diffusion. The crystallization conditions, which yielded crystals with a needle morphology arranged as single crystals or point-originated clusters, were comprised of 80 mM sodium cacodylate pH 6.0–7.4, 13–14%(w/v) PEG 8000, 120–160 mM calcium acetate, 15.0–17.5%(w/v) glycerol. 0.3–1.5 µl drops with different volume ratios of protein solution (6.5–7.5 mg ml−1 in 20 mM HEPES pH 7.4, 200 mM NaCl) and reservoir solution were used at 281 and 293 K, equilibrating against 40 µl reservoir solution. Crystals were briefly soaked in cryoprotectant solutions and flash-cooled in liquid N2. The detailed conditions used to obtain the crystals used for data collection are given in Table 1 ▸.
Table 1. Crystallization.
Crystal form | 1 | 2 |
---|---|---|
Method | Sitting-drop vapour diffusion | Sitting-drop vapour diffusion |
Plate type | Swissci 3-drop 96-well plate | Swissci 3-drop 96-well plate |
Temperature (K) | 293 | 281 |
Protein concentration (mg ml−1) | 7.5 | 7 |
Buffer composition of protein solution | 20 mM HEPES pH 7.4, 200 mM NaCl | 20 mM HEPES pH 7.4, 200 mM NaCl |
Composition of reservoir solution | 80 mM sodium cacodylate pH 6.0, 14% PEG 8000, 160 mM calcium acetate, 15% glycerol | 80 mM sodium cacodylate pH 7.0, 13% PEG 8000, 160 mM calcium acetate, 15% glycerol |
Volume and ratio (protein:well solution) of drop | 0.3 µl (1:1) | 1.5 µl (1:2) |
Volume of reservoir (µl) | 40 | 40 |
Cryoprotection solution | 75%(v/v) reservoir + 25%(v/v) PEG 200 | 80%(v/v) reservoir + 20%(v/v) glycerol |
2.3. Data collection, structure solution and refinement
The MmGADL1 structure was solved from the two crystal forms by molecular replacement in Phaser (McCoy et al., 2007 ▸) using the structure of HsCSAD (PDB entry 2jis; Structural Genomics Consortium, unpublished work) as the search model. Crystal form 1 diffracted to 3 Å resolution, while crystal form 2, which was used for initial structure solution, diffracted to 2.4 Å resolution; the latter suffered from near-perfect pseudomerohedral twinning and high translational pseudosymmetry. Owing to these observations, both crystal forms were solved and initially refined, and the lower resolution structure, which completely lacked twinning and pseudotranslation, was considered to be better for final refinement. In essence, despite the higher nominal resolution, the twinned crystal suffering from pseudotranslation gave lower-quality electron-density maps. The twinning and pseudotranslation operations are given in Table 2 ▸. NCS restraints were employed throughout refinement. Refinement was performed with phenix.refine (Afonine et al., 2012 ▸) and model building with Coot (Emsley & Cowtan, 2004 ▸). The structure was validated with MolProbity (Chen et al., 2010 ▸). Data collection and refinement statistics can be found in Table 2 ▸. The resolution limits used were based on recent studies (Karplus & Diederichs, 2015 ▸) showing that useful information is available for refinement even for data with a CC1/2 much lower than 50%.
Table 2. Data collection, processing and structure refinement.
Crystal form | 1 | 2 |
---|---|---|
Data-collection statistics | ||
Wavelength (Å) | 1.0332 | 0.9763 |
Space group | C2 | P21 |
a, b, c (Å) | 137.4, 80.6, 128.5 | 80.9, 121.7, 101.1 |
α, β, γ (°) | 90, 117.9, 90 | 90, 90.08, 90 |
Resolution range (Å) | 50–3.00 (3.08–3.00) | 50–2.40 (2.46–2.40) |
Completeness (%) | 99.4 (99.5) | 98.7 (95.9) |
Multiplicity | 6.4 (6.0) | 3.6 (3.1) |
〈I/σ(I)〉† | 7.1 (0.7) | 5.9 (0.9) |
R meas | 0.328 (3.535) | 0.188 (1.466) |
R p.i.m. | 0.130 (1.443) | 0.099 (0.832) |
CC1/2 (%) | 98.9 (28.4) | 99.3 (61.4) |
Overall B factor from Wilson plot (Å2) | 67 | 44 |
Refinement statistics | ||
Resolution range (Å) | 50–3.0 | — |
Final R cryst | 0.236 | — |
Final R free | 0.288 | — |
R.m.s.d.s | ||
Bond lengths (Å) | 0.003 | — |
Bond angles (°) | 0.7 | — |
Average B factor (Å2) | 91.0 | — |
Ramachandran plot | ||
Favoured (%) | 92.0 | — |
Outliers (%) | 0.6 | — |
MolProbity score [percentile] | 1.98 [99th] | — |
Twin operator/twin fraction (%) | — | h, −k, −l/45 |
Pseudotranslation operator/fraction (%) | — | 0.060, −0.500, 0.417/38 |
The mean I/σ(I) in the outermost shell falls below 2.0 at 3.3 Å for crystal form 1 and 2.7 Å for crystal form 2.
2.4. Small-angle X-ray scattering
Synchrotron SAXS data were collected on the EMBL/DESY BioSAXS beamline P12 (Blanchet et al., 2015 ▸). The protein was at 1.6–6.5 mg ml−1 in 20 mM HEPES pH 7.4, 200 mM NaCl. The scattering data were processed and analyzed with programs from the ATSAS package (Konarev et al., 2006 ▸). The molecular weight was determined by comparison of the forward scattering intensity, I(0), with a fresh monomeric bovine serum albumin standard. Models of MmGADL1 were built with GASBOR (Svergun et al., 2001 ▸) and SREFLEX (Panjkovich & Svergun, 2016 ▸), using data extrapolated to zero concentration. Theoretical scattering curves from crystal structure coordinates were calculated with CRYSOL (Svergun et al., 1995 ▸). Model superposition was performed using SUPCOMB (Kozin & Svergun, 2001 ▸). Details of SAXS data collection, processing and analysis are given in Table 3 ▸, and the raw SAXS scattering data are provided as Supporting Information.
Table 3. Small-angle X-ray scattering.
Data-collection parameters | |
Protein | MmGADL1, His-tagged |
Instrument | P12, PETRA III, EMBL/DESY with Dectris PILATUS 2M detector (Blanchet et al., 2015 ▸) |
Wavelength (nm) | 0.124 |
Beam size (µm) | 200 × 120 |
Detector distance (m) | 3.1 |
Angular range (nm−1) | 0.018–4.607 |
Exposure time per frame (s) | 0.045 |
No. of frames per sample | 20 |
Monitoring for radiation damage | Data frame-by-frame comparison |
Scaling method | Buffer-subtracted data normalized to 1 mg ml−1 |
Normalization | To transmitted intensity by beamstop counter (Blanchet et al., 2015 ▸) |
Concentration range (mg ml−1) | 1.6, 3.3, 6.5 |
Temperature (K) | 293 |
Structural parameters | |
R g from crystal structure (nm) | 2.95 |
D max from crystal structure (nm) | 10.67 |
Guinier analysis | |
I(0) from Guinier (relative) | 2519 |
R g from Guinier (nm) | 3.62 |
s min (nm−1) | 0.143 |
sR g range | 0.52–1.30 |
Fidelity | 0.92 |
p(r) analysis | |
I(0) from p(r) (relative) | 2557 |
R g from p(r) (nm) | 3.80 |
D max (nm) | 13.67 |
s range (nm−1) | 0.143–1.98 |
Quality of fit (total estimate from GNOM) | 0.83 |
Porod volume (nm3) (ratio to calculated molecular mass in kDa) | 196 (1.6) |
Molecular-mass determination | |
Molecular mass from I(0) using p(r) (kDa) (ratio to theoretical monomer) | 121.0 (2.0) |
Molecular mass from I(0) using Guinier (kDa) (ratio to theoretical monomer) | 120.6 (2.0) |
Theoretical monomeric molecular mass from sequence (kDa) | 60.4 |
Shape and atomistic modelling | |
CRYSOL (comparison to crystal structure) | |
χ2 value versus crystal structure | 41.9 |
s range (nm−1) | 0.018–4.607 |
GASBOR (ab initio chain-like modelling) | |
χ2 value | 1.7 |
s range (nm−1) | 0.143–4.607 |
Symmetry | P2 |
SREFLEX (modelling of flexibility based on crystal structure) | |
χ2 value | 5.7 |
s range (nm−1) | 0.018–4.607 |
Software | |
Data processing and basic analyses | SASFLOW (Franke et al., 2012 ▸; Blanchet et al., 2015 ▸) and PRIMUSqt (Petoukhov et al., 2012 ▸) |
Distance distribution analysis | GNOM (Svergun, 1992 ▸) through PRIMUSqt (Petoukhov et al., 2012 ▸) |
Ab initio analysis | GASBOR (Svergun et al., 2001 ▸) via ATSAS online (https://www.embl-hamburg.de/biosaxs/atsas-online/) |
Conformational analysis | SREFLEX (Panjkovich & Svergun, 2016 ▸) via ATSAS online (https://www.embl-hamburg.de/biosaxs/atsas-online/) |
Comparison to crystal structure | CRYSOL (Svergun et al., 1995 ▸) |
Graphics representation | PyMOL (http://www.pymol.org) |
Extinction coefficient estimate | ProtParam (Gasteiger et al., 2005 ▸) |
2.5. Sequence and structure analysis
APBS (Unni et al., 2011 ▸), UCSF Chimera (Pettersen et al., 2004 ▸), PyMOL (http://www.pymol.org), ProtParam (Gasteiger et al., 2005 ▸), PDBeFold (Krissinel & Henrick, 2004 ▸), MUSCLE (Edgar, 2004 ▸) and ESPript3.0 (Robert & Gouet, 2014 ▸) were used for bioinformatics and structure analyses.
3. Results and discussion
3.1. The crystal structure of MmGADL1
Initial screening for crystallization conditions of MmGADL1 resulted in a single condition that produced diffracting crystals. Crystals formed with a needle morphology, often growing in bunches or clusters and generally being very thin, with maximum lengths reaching 500 µm. The diffraction quality was initially poor, with diffraction limits of around 6–7 Å and highly smeared reflections. By optimizing the size, the amount of nucleation, and the general appearance of the crystals, the conditions given in Table 1 ▸ produced thin but nonfragile crystals that allowed structure refinement in two crystal forms to resolutions of 2.4 and 3.0 Å; the higher resolution data set was plagued by significant twinning and pseudotranslation (Table 2 ▸). Thus, the structure of the nontwinned crystal form is discussed here; essentially all features can also be seen in the twinned crystal.
The crystal structure revealed a single MmGADL1 homodimer in the asymmetric unit, which was the expected oligomeric state based on other PLP-dependent decarboxylases (Fig. 1 ▸ a). For both chains, residues 11–502 could be built, with the flexible loop common to PLP-dependent decarboxylases (Fenalti et al., 2007 ▸) being absent from the electron density (approximately residues 340–350). The overall conformation of the two chains was nearly identical (Fig. 1 ▸ b).
In the crystal lattice, the protein dimers form layers in the xy plane, separated by a rather uniform spacing (Fig. 1 ▸ c). As the first ∼30 amino acids of the tagged protein were not visible, they are most likely to occupy the space between protein dimers in the crystal. This is the likely source of the high mosaicity and incomplete lattice arrangement in the current MmGADL1 crystals.
Both active sites in the dimer are occupied by the PLP cofactor, which is covalently bound to the N∊ atom of Lys314 in each chain through a Schiff base linkage, being located at the dimer interface (Fig. 1 ▸ d). Closer observation of the active-site cavity reveals that only the active imine of the linked PLP is solvent-exposed, and it resides at the end of a narrow cavity, which represents the substrate-binding pocket (Fig. 2 ▸ a). Electrostatic surface analysis reveals the GADL1 active site to have a high positive charge potential (Fig. 2 ▸ b). This is logical, as the substrates of GADL1 are acidic amino acids; the basic nature of the binding cavity is involved in electrostatic interactions that attract and bind the substrate, orienting it correctly for catalysis.
In our earlier work, we showed that GADL1 can use aspartate and CSA as substrates, but not glutamate (Winge et al., 2015 ▸). While the catalytic cavities of GAD and GADL1 are very similar, it is currently difficult to pinpoint which features of the active site might be responsible for selectivity between such similar substrates. High-resolution structures of GADL1 and its closest homologues with bound active-site ligands will clearly be required. Importantly, a large part of the active-site cavity wall will be formed by the flexible loop in the substrate-bound state; the flexible loop is invisible in most PLP-dependent decarboxylase crystal structures, but harbours a Tyr residue that is likely to be important for catalysis.
3.2. MmGADL1 adopts an open conformation in solution
We used SAXS to validate the crystal structure and to determine the conformation of MmGADL1 in solution (Fig. 3 ▸, Table 3 ▸). As is apparent from the scattering data and the dimensionless Kratky plot, GADL1 presents a folded shape. While the molecular mass calculated from the forward scattering intensity accurately matches that of a dimer, the theoretical scattering curve calculated from the crystal structure differs significantly. The shape in solution is more elongated than in the crystal. The radii of gyration between the theoretical scattering curve from the crystal structure and the experimental value from Guinier analysis differ by nearly 1 nm, indicating a large difference in conformation. The maximum diameter is 3 nm larger in solution than in the crystal state.
The GASBOR chain-like dummy residue model of MmGADL1 is elongated compared with the crystal structure (Fig. 3 ▸ e). Attempts to model the missing N-terminal portion, while keeping the dimeric crystal structure fixed, did not fit the experimental SAXS data well (data not shown). We thus employed the recently described SREFLEX method (Panjkovich & Svergun, 2016 ▸) to take advantage of normal-mode analysis of the crystal structure in SAXS modelling. The SREFLEX model fits the scattering data well and suggests a clearly loosened solution conformation (Fig. 3 ▸ f), in contrast to the compact globular structures observed for PLP-dependent decarboxylases in the crystalline state. The open conformation is not similar to the open conformation observed for DOPA decarboxylase in the crystalline state (Giardina et al., 2011 ▸; Fig. 3 ▸ g), in which case the opening occurs in the centre of the dimer. The observed open–close movement is likely to be of functional relevance in the GADL1 catalytic cycle. Whether the different conformations are linked to the binding of ligands remains to be studied. While our GADL1 preparation is enzymatically active (Winge et al., 2015 ▸), and the crystal is apparently fully occupied with covalently bound PLP, we cannot currently rule out the presence of PLP-deficient GADL1 in the purified SAXS sample, since crystallization might have enriched a cofactor-bound conformation of the protein.
3.3. Comparison to other PLP-dependent decarboxylases
While MmGADL1 and its homologues show low sequence conservation, apart from a few fully conserved core elements around the active site (Fig. 4 ▸ a), comparison of the structures of MmGADL1 and its homologues reveals a conserved structural fold with little variance in the arrangement of the PLP-linked Lys residue (Figs. 4 ▸ b and 4 ▸ c, Table 4 ▸). The sequence conservation between MmGADL1, HsCSAD and HsGADs (Fenalti et al., 2007 ▸) is higher than those with human histidine decarboxylase (HDC; Komori et al., 2012 ▸) and DOPA decarboxylase (DDC; Giardina et al., 2011 ▸; Winge et al., 2015 ▸). The latter present similar levels of sequence homology to GADL1 as the bacterial enzymes Sphaerobacter thermophilus PLP-dependent decarboxylase (StPDD), Vibrio parahaemolyticus GAD (VpGAD) and the tryptamine-synthesizing enzyme from the gut bacterium Ruminococcus gnavus (RUMGNA_01526; Williams et al., 2014 ▸). Despite low sequence homology, the R. gnavus enzyme displays high structural similarity to GADL1, suggesting conservation of the fold of PLP-dependent decarboxylases involved in neurotransmitter synthesis. It is interesting to note that the absence of PLP in the active site neither alters the overall tightness of the superposed proteins nor changes the position of the conserved Lys in most structures. In the future, experimental solution-state methods, such as SAXS, may help to distinguish functionally relevant conformational states from possible crystallographic artifacts. These observations conflict with earlier results described for HsDDC in the beginning of its PLP accumulation-dependent conformational landscape, where a more open conformation was evident in the crystalline state with the active-site Lys residue oriented away from the PLP-binding pocket (Giardina et al., 2011 ▸).
Table 4. Structural homologues of MmGADL1.
Protein | Organism | PDB entry | Reference | Chain | Q-score | R.m.s.d. (Å) | Sequence identity (%) | UniProtKB entry | Aligned residues |
---|---|---|---|---|---|---|---|---|---|
MmGADL1 | Mus musculus | 6enz | This study | A | — | — | — | E9QP13 | 1–502 |
HsCSAD | Homo sapiens | 2jis | Unpublished work | B | 0.586 | 0.85 | 62.0 | Q9Y600 | 1–493 |
HsGAD65 | Homo sapiens | 2okk | Fenalti et al. (2007 ▸) | A | 0.565 | 1.06 | 49.4 | Q05329 | 88–584 |
HsGAD67 | Homo sapiens | 2okj | Fenalti et al. (2007 ▸) | B | 0.532 | 1.15 | 50.9 | Q9925 | 93–594 |
StPDD | Sphaerobacter thermophilus | 4rit | Unpublished work | B | 0.461 | 1.96 | 28.9 | D1C7D8 | 1–483 |
RUMGNA_01526 | Ruminococcus gnavus | 4obu | Williams et al. (2014 ▸) | H | 0.492 | 1.79 | 25.6 | A7B1V0 | 1–490 |
VpGAD | Vibrio parahaemolyticus | 2qma | Unpublished work | B | 0.442 | 2.16 | 25.8 | Q87NC6 | 464–957 |
HsHDC | Homo sapiens | 4e1o | Komori et al. (2012 ▸) | C | 0.425 | 2.13 | 26.1 | P19113 | 2–477 |
HsDDC | Homo sapiens | 3rbl | Giardina et al. (2011 ▸) | A | 0.397 | 2.61 | 23.3 | P20711 | 1–480 |
The substrate specificity and physiological function of GADL1 remain enigmatic. However, the conserved structural details and distinct expression patterns of GADL1 suggest that it plays a specific physiological role. Variants of GADL1 have been linked to lithium response in bipolar disorder patients (Chen et al., 2014 ▸), suggesting a role for GADL1 in lithium pharmacodynamics or kinetics. However, these findings have not been replicated by others, and they have been subject to much controversy (Birnbaum et al., 2014 ▸; Cruceanu et al., 2015 ▸; Kotambail et al., 2015 ▸; Winge et al., 2015 ▸; Chen et al., 2016 ▸).
Owing to their common mechanistic features, many PLP-dependent enzymes are able to catalyze multiple biochemical reactions, making it difficult to define their primary biological function (Percudani & Peracchi, 2003 ▸). Of the known GADL1 substrates, Asp appears as the most characteristic substrate for GADL1 (Winge et al., 2015 ▸), although the K m is relatively high and the catalytic efficiency is low. Nevertheless, the K m of GADL1 for Asp is in the physiological range, and one could speculate that GADL1 is involved in sensing selected metabolite levels. Relatively low binding affinity is a hallmark of many proteins with signalling roles, which have evolved as sensors of ligand availability; such proteins include, for example, the calcium sensors calmodulin and annexin (Kursula, 2014 ▸; Monastyrskaya et al., 2007 ▸). Conformational flexibility, as observed here for GADL1 in solution, might have relevance in such a function.
4. Concluding remarks
The physiological functions and enzymatic properties of GADL1 are subject to further studies. The structure of MmGADL1 and its flexibility in solution, coupled to structural conservation with other PLP-dependent enzymes, point towards functional relevance of these features within the enzyme family. Important future work will concentrate on high-resolution structural details of substrate and inhibitor binding by GADL1, and on comparing these with those of CSAD, GAD and other PLP-dependent decarboxylases. Crucial topics to address will include the fine details of substrate specificity determinants in PLP-dependent decarboxylases, as well as the relevance of the conformational changes observed here to the catalytic cycle of this family of enzymes.
Supplementary Material
ASCII file representing the background-corrected SAXS scattering profile, extrapolated to zero concentration, with errors.. DOI: 10.1107/S2053230X17017848/tb5122sup1.txt
Supplementary Figure 1. Dependence of Rg and I(0) on sample concentration in SAXS.. DOI: 10.1107/S2053230X17017848/tb5122sup2.pdf
Raw SAXS scattering data with all concentrations.. DOI: 10.1107/S2053230X17017848/tb5122sup3.zip
Acknowledgments
We gratefully acknowledge access to the synchrotron-radiation facilities and the outstanding beamline support at EMBL/DESY, Hamburg, Germany.
Funding Statement
This work was funded by Helse Vest grant to Jan Haavik. Norges Forskningsråd grant to Petri Kursula. Sigrid Juséliuksen Säätiö grant to Petri Kursula. Stiftelsen Kristian Gerhard Jebsen grant to Jan Haavik. Seventh Framework Programme grant 602805 to Jan Haavik.
References
- Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H. & Adams, P. D. (2012). Acta Cryst. D68, 352–367. [DOI] [PMC free article] [PubMed]
- Baekkeskov, S., Aanstoot, H.-J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H. & Camilli, P.-D. (1990). Nature (London), 347, 151–156. [DOI] [PubMed]
- Birnbaum, R., Shin, J. H. & Weinberger, D. (2014). N. Engl. J. Med. 370, 1855–1856. [DOI] [PubMed]
- Blanchet, C. E., Spilotros, A., Schwemmer, F., Graewert, M. A., Kikhney, A., Jeffries, C. M., Franke, D., Mark, D., Zengerle, R., Cipriani, F., Fiedler, S., Roessle, M. & Svergun, D. I. (2015). J. Appl. Cryst. 48, 431–443. [DOI] [PMC free article] [PubMed]
- Chen, C.-H. et al. (2014). N. Engl. J. Med. 370, 119–128.
- Chen, C.-K., Lee, C.-S., Chen, H.-Y., Wu, L. S.-H., Chang, J.-C., Liu, C.-Y. & Cheng, A. T.-A. (2016). BJPsych Open, 2, 301–306. [DOI] [PMC free article] [PubMed]
- Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. [DOI] [PMC free article] [PubMed]
- Cruceanu, C., Alda, M., Dion, P. A., Turecki, G. & Rouleau, G. A. (2015). Am. J. Psychiatry, 172, 94–95. [DOI] [PubMed]
- Edgar, R. C. (2004). Nucleic Acids Res. 32, 1792–1797. [DOI] [PMC free article] [PubMed]
- Eliot, A. & Kirsch, J. (2004). Annu. Rev. Biochem. 73, 383–415. [DOI] [PubMed]
- El-Sayed, A. S. & Shindia, A. A. (2011). Targets in Gene Therapy, edited by Y. You, ch. 7. Rijeka: Intech. https://doi.org/10.5772/17449.
- Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132. [DOI] [PubMed]
- Fenalti, G. et al. (2007). Nature Struct. Mol. Biol. 14, 280–286. [DOI] [PubMed]
- Franke, D., Kikhney, A. G. & Svergun, D. I. (2012). Nucl. Instrum. Methods Phys. Res. A, 689, 52–59.
- Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D. & Bairoch, A. (2005). The Proteomics Protocols Handbook, edited by J. M. Walker, pp. 571–607. Totowa: Humana Press.
- Giardina, G., Montioli, R., Gianni, S., Cellini, B., Paiardini, A., Voltattorni, C. B. & Cutruzzolà, F. (2011). Proc. Natl Acad. Sci. USA, 108, 20514–20519. [DOI] [PMC free article] [PubMed]
- Hammarström, M., Woestenenk, E., Hellgren, N., Härd, T. & Berglund, H. (2006). J. Struct. Funct. Genomics, 7, 1–14. [DOI] [PubMed]
- Karplus, P. A. & Diederichs, K. (2015). Curr. Opin. Struct. Biol. 34, 60–68. [DOI] [PMC free article] [PubMed]
- Komori, H., Nitta, Y., Ueno, H. & Higuchi, Y. (2012). J. Biol. Chem. 287, 29175–29183. [DOI] [PMC free article] [PubMed]
- Konarev, P. V., Petoukhov, M. V., Volkov, V. V. & Svergun, D. I. (2006). J. Appl. Cryst. 39, 277–286.
- Kotambail, A., Mathur, A., Bhat, S. M., Rai, P. S., Sharma, P. S. & Satyamoorthy, K. (2015). Psychiatr. Genet. 25, 39–40. [DOI] [PubMed]
- Kozin, M. B. & Svergun, D. I. (2001). J. Appl. Cryst. 34, 33–41.
- Krissinel, E. & Henrick, K. (2004). Acta Cryst. D60, 2256–2268. [DOI] [PubMed]
- Kursula, P. (2014). Amino Acids, 46, 2295–2304. [DOI] [PubMed]
- Liu, P., Ge, X., Ding, H., Jiang, H., Christensen, B. M. & Li, J. (2012). J. Biol. Chem. 287, 40898–40906. [DOI] [PMC free article] [PubMed]
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. [DOI] [PMC free article] [PubMed]
- Min, J., Senut, M., Rajanikant, K., Greenberg, E., Bandagi, R., Zemke, D., Mousa, A., Kassab, M., Farooq, M. U., Gupta, R. & Majid, A. (2008). J. Neurosci. Res. 86, 2984–2991. [DOI] [PMC free article] [PubMed]
- Monastyrskaya, K., Babiychuk, E. B., Hostettler, A., Rescher, U. & Draeger, A. (2007). Cell Calcium, 41, 207–219. [DOI] [PubMed]
- Paiardini, A., Contestabile, R., Buckle, A. M. & Cellini, B. (2014). Biomed. Res. Int. 2014, 856076. [DOI] [PMC free article] [PubMed]
- Panjkovich, A. & Svergun, D. I. (2016). Phys. Chem. Chem. Phys. 18, 5707–5719. [DOI] [PubMed]
- Park, H., Han, K., Shin, J., Park, J., Song, K. & Kim, D. (2014). J. Korean. Neurosurg. Soc. 55, 125–130. [DOI] [PMC free article] [PubMed]
- Percudani, R. & Peracchi, A. (2003). EMBO Rep. 4, 850–854. [DOI] [PMC free article] [PubMed]
- Petoukhov, M. V., Franke, D., Shkumatov, A. V., Tria, G., Kikhney, A. G., Gajda, M., Gorba, C., Mertens, H. D. T., Konarev, P. V. & Svergun, D. I. (2012). J. Appl. Cryst. 45, 342–350. [DOI] [PMC free article] [PubMed]
- Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. & Ferrin, T. E. (2004). J. Comput. Chem. 25, 1605–1612. [DOI] [PubMed]
- Robert, X. & Gouet, P. (2014). Nucleic Acids Res. 42, W320–W324. [DOI] [PMC free article] [PubMed]
- Sköldberg, F., Rorsman, F., Perheentupa, J., Landin-Olsson, M., Husebye, E., Gustafsson, J. & Kämpe, O. (2004). J. Clin. Endocrinol. Metab. 89, 1636–1640. [DOI] [PubMed]
- Svergun, D. I. (1992). J. Appl. Cryst. 25, 495–503.
- Svergun, D., Barberato, C. & Koch, M. H. J. (1995). J. Appl. Cryst. 28, 768–773.
- Svergun, D. I., Petoukhov, M. V. & Koch, M. H. J. (2001). Biophys. J. 80, 2946–2953. [DOI] [PMC free article] [PubMed]
- Unni, S., Huang, Y., Hanson, R., Tobias, M., Krishnan, S., Li, W. W., Nielsen, J. E. & Baker, N. A. (2011). J. Comput. Chem. 32, 1488–1491. [DOI] [PMC free article] [PubMed]
- Williams, B. B., Van Benschoten, A. H., Cimermancic, P., Donia, M. S., Zimmermann, M., Taketani, M., Ishihara, A., Kashyap, P. C., Fraser, J. S. & Fischbach, M. A. (2014). Cell Host Microbe, 16, 495–503. [DOI] [PMC free article] [PubMed]
- Winge, I., Teigen, K., Fossbakk, A., Mahootchi, E., Kleppe, R., Sköldberg, F., Kämpe, O. & Haavik, J. (2015). Neurochem. Int. 90, 173–184. [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
ASCII file representing the background-corrected SAXS scattering profile, extrapolated to zero concentration, with errors.. DOI: 10.1107/S2053230X17017848/tb5122sup1.txt
Supplementary Figure 1. Dependence of Rg and I(0) on sample concentration in SAXS.. DOI: 10.1107/S2053230X17017848/tb5122sup2.pdf
Raw SAXS scattering data with all concentrations.. DOI: 10.1107/S2053230X17017848/tb5122sup3.zip